rosiglitazone has been researched along with Experimental Hepatoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, HL; Cheng, AS; Cheung, KF; Chu, ES; Feng, H; Lam, CN; Shen, B; Sung, JJ; Teoh, N; To, KF; Wang, S; Wu, CW; Yu, J; Zhao, J | 1 |
| Guo, YT; Leng, XS; Li, T; Lin, XH; Zhao, JM; Zhu, JY | 1 |
2 other study(ies) available for rosiglitazone and Experimental Hepatoma
| Article | Year |
|---|---|
Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.
Topics: Adenoviridae; Alkylating Agents; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diethylnitrosamine; Gene Expression Profiling; Growth Differentiation Factor 15; Humans; Hypoglycemic Agents; Liver Neoplasms, Experimental; Male; Mice; Mice, Knockout; Oligonucleotide Array Sequence Analysis; PPAR gamma; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2010 |
[Pexoxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats].
Topics: Animals; Antineoplastic Agents; Chromans; Diethylnitrosamine; Ligands; Liver Neoplasms, Experimental; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |